Title21 Joins Global Blood and Cell Advocacy Roster
Title21 Health Solutions, a portfolio company specialising in life science regulatory support, has joined the Blood and Cells Advocacy Roster (BCAR) – an industry collaboration centred on championing the importance of blood and cell therapies, and pushing for wider patient access to advanced treatments.
Established in 2024, BCAR positions itself as an international body with a clear mission: to elevate the role of the blood industry while helping remove barriers that can slow the pathway from innovation to patient care.
In a sector where regulation, compliance, and operational rigour are inseparable from clinical progress, the addition of a technology-driven regulatory specialist is designed to strengthen the group’s collective voice.
One of the most striking realities underpinning BCAR’s work is the scale and reach of community blood centres. These centres supply almost 60% of the United States’ blood supply and around 25% of Canada’s.
Across North America, more than 700 donor facilities serve over 1,100 communities – a footprint that makes blood collection and distribution one of healthcare’s most vital and widespread infrastructures.
That infrastructure, however, is no longer limited to transfusions alone. Many community blood centres are now leveraging their expertise to provide specialised blood products for cell therapies – a shift that could increase nationwide access to medical innovations and support the growing demand for complex, next-generation treatments.
BCAR’s founder highlighted why Title21’s inclusion matters now, noting that as innovators in regulatory and compliance software working in the blood industry, Title21 brings a vital technology perspective to the collaboration’s broader advocacy efforts.
The goal is not only to promote the significance of blood and cell therapies, but to ensure the systems surrounding them can scale safely, consistently, and compliantly.
The steering committee behind BCAR reflects the breadth of stakeholders needed to move the sector forward. Members include America’s Blood Centers (ABC), the Association for the Advancement of Blood & Biotherapies (AABB), BioBridge Global, Blood Centers of America (BCA), Terumo Blood and Cell Technologies, Title21, and Vitalant – blending operational expertise, clinical standards, and industry leadership under one roof.
From Title21’s perspective, the motivation is rooted in both fundamentals and future-facing ambition.
The company’s chief commercial officer said blood is not only foundational to healthcare, but a critical enabler of innovation in cell and gene therapies. By combining robust technology with the expertise of blood centres, Title21 believes the industry can streamline processes, strengthen compliance, and ultimately improve patient outcomes – a statement that speaks to the high-stakes reality of delivering advanced therapies at scale.
Title21 was founded in 2001 and has built its niche around supporting life science regulatory needs, with a focus on compliance and the systems that help organisations meet stringent standards.
Today, it operates as a portfolio company of Archimed, a leading growth equity enterprise – a backdrop that signals both maturity and momentum as the company expands its influence across adjacent healthcare ecosystems.
Conclusion
With BCAR’s advocacy push gaining pace since its establishment in 2024, Title21’s entry brings a practical and increasingly essential dimension: the technology and compliance infrastructure that can help blood centres and therapy developers work faster, safer, and more consistently.
As community blood centres continue to underpin the majority of blood supply across the US – and a significant portion in Canada – their growing role in supporting cell therapies makes collaboration across the sector more than a strategic choice; it becomes a necessity.
In joining BCAR’s international roster and steering committee, Title21 is stepping into a wider conversation about how the blood industry can power the next era of treatment – and how the right systems can help ensure those innovations reach the patients who need them most.
News Credits: Title21 Health Solutions joins the Blood and Cells Advocacy Roster
Things you may also like:
- Lindus Health and Quotient Sciences Partner
- Quorn Strips Back the Label: Fillets Reformulated
- GRI Bio Reports Positive Phase 2a Topline Data for GRI-0621